ArticleBMC cancer2025

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients.

Shusheng Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.